SLC5A2 and type 2 diabetes mellitus: Sodium glucose cotransporter 2 (SGLT2) inhibitors have been developed as a new class of oral hypoglycemic drugs that inhibit glucose reabsorption at the proximal tubules for the treatment of T2DM [23, 24].